NANS 2020: SPR Therapeutics' Nerve Stimulation System Provides 12-Month Pain Relief After 60-Day Treatment
SPR Therapeutics said its SPRINT neurostimulation technology achieved a 63% reduction in average pain intensity in patients with chronic low back pain.
You may also be interested in...
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
SPR Therapeutics' Sprint percutaneous peripheral nerve stimulator proved safe and effective at reducing pain in post-amputation patients in a new 28-patient randomized study.
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.